6533b852fe1ef96bd12aaf12
RESEARCH PRODUCT
Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions
Irene KrämerJeanette Kaisersubject
Time FactorsStability studyDrug StorageSodiumchemistry.chemical_elementAntineoplastic AgentsInjection concentratechemistry.chemical_compoundGlucose infusionDrug StabilitymedicineClofarabinePharmacology (medical)Clofarabine InjectionInfusions IntravenousChromatography High Pressure LiquidChromatographyAdenine Nucleotidesbusiness.industryReproducibility of ResultsPolyethylenePharmaceutical SolutionsPolyvinyl chlorideOncologychemistryArabinonucleosidesbusinessClofarabinemedicine.drugdescription
Purpose: The aim of this study was to investigate the physicochemical stability of clofarabine (CAFdA) injection concentrate and ready-to-use CAFdA infusion solutions over a prolonged period of 28 days. Methods: To determine the stability of CAFdA infusion solutions, the injection concentrate (Evoltra®, 1 mg/mL, Genzyme) was diluted either with 0.9% sodium chloride or 5% glucose infusion solution. The resulting concentrations of 0.2 mg/mL or 0.6 mg/mL, respectively, were chosen to represent the lower and upper limit of the ordinary concentration range. Test solutions were stored under refrigeration (2–8°C) or at room temperature either light protected or exposed to light. CAFdA concentrations and pH values were determined at different time intervals throughout a 28-day storage period. Compatibility of diluted CAFdA infusion solutions (0.1–0.4 mg/mL) with different container materials (polyvinyl chloride (PVC), glass, and polypropylene/polyethylene (PP/PE)) was tested over a 48-h storage period. CAFdA concentrations were measured by a stability-indicating reversed phase high-performance liquid chromatography (HPLC) assay with ultraviolet detection. Results: CAFdA injection concentrate and CAFdA infusion solutions remained physicochemically stable (>90% CAFdA) for 4 weeks. Results are independent of storage conditions, drug concentrations (0.2, 0.6, and 1.0 mg/mL) and diluents (0.9% sodium chloride, 5% glucose infusion solution). Adsorption of CAFdA to container material can be excluded. Conclusions: CAFdA injection concentrate and diluted infusion solutions in commonly used vehicles are stable for at least 28 days either refrigerated or at room temperature. Physicochemical stability favors pharmacy-based centralized preparation. Due to microbiological reasons, strict aseptic handling and storage of the products under refrigeration is recommended.
year | journal | country | edition | language |
---|---|---|---|---|
2011-11-10 | Journal of Oncology Pharmacy Practice |